Lumosa Therapeutics Co Ltd · TPEX:6535
Lumosa Therapeutics — Institutional Investor Conference 2026
19 slides from Lumosa Therapeutics's conference presentation, May 15, 2026
Slide 1: Lumosa Therapeutics
Lumosa Therapeutics (TPEX:6535) 2026/5 1
Slide 2: Disclaimer
DISCLAIMER • This presentation and related information released concurrently contain forward-looking statements regarding the Company's operational outlook, financial condition, and business forecasts. These statements are based on information obtained from both internal and external sources and rel
Slide 3: LT3001 (Odatroltide) – A First-In-Class Small Molecule for Acute Ischemic Stroke
LT3001 (Odatroltide)– A First-In-Class Small Molecule for the Treatment of Acute Ischemic Stroke Phase 3 Ready Program 2026 3
Slide 4: Focal Point of the Conference
Focal Point of the Conference • LT3001 Monotherapy • Data from the Phase 2 clinical trial demonstrated efficacy signals, showing more pronounced therapeutic potential in moderate-to-severe and disabling acute ischemic stroke (AIS) populations. • LT3001-301 trial (Phase 2/3 study): protocol design co
Slide 5: Acute Ischemic Stroke – Limited Efficacy with Current Therapies, Urgent Need for Improved Treatment Options
Acute Ischemic Stroke – Limited Efficacy with Current Therapies, Urgent Need for Improved Treatment Options Large Vessel Occlusion Medium Vessel Small Vessel Occlusion Occlusion Within 4.5 Hrs Post-Stroke Onset IV tPA / TNK (intravenous thrombolytic agent) LT3001 Target 2 1 1 Monotherapy: EVT + LT30
Slide 6: Becoming a new treatment option for stroke patients beyond 4.5 hours post-stroke onset
1 Becoming a new treatment option for stroke patients beyond 4.5 hours post-stroke onset
Slide 7: LT3001-202: Meaningful Functional Recovery in High-Need AIS
LT3001-202: Meaningful Functional Recovery in High-Need AIS Moderate to severe and Stroke population in disabled stroke patients urgent need of treatment Arm Weakness Leg Weakness Aphasia LT3001-202 Phase 2 result (Disabling subgroups) Data from CN Phase 2 trial Disabled Outcome Feature at Day-90 0.
Slide 8: LT3001-301: Phase 2/3 Seamless Bridging Trial
LT3001-301: Phase 2/3 Seamless Bridging Trial Regulatory approval in China x Global licensing 2026Q4 2027-2028 2030 Phase 2 Phase 3 0.025, 0.05 mg/kg, placebo Selected dose, placebo (~300 patients) (Improvement rate = 8%,~1200 patients) 1. Optimal dose selection 2. Confirmation of patient sample siz
Slide 9: LT3001-206: Imaging-Centric Mechanistic Research Adding Value for Global Licensing
LT3001-206: Imaging-Centric Mechanistic Research Adding Value for Global Licensing LT3001 enhances effective Study Goal: Study Design: reperfusion: Serial imaging assessments to evaluate • Open label, single-arm study, with intracranial vascular recanalization and multiple-dose administration • Mark
Slide 10: Concomitant use with EVT to enhance treatment effect
Concomitant use with EVT to 2 enhance treatment effect LT3001-203 Part A (n=24, US&TW) single dose LT3001 + EVT Status: Jan 2026 Recruitment completed; Apr 2026 DSMB suggestion: Safe to proceed
Slide 11: Supporting Evidence: Potential Effect on Large Vessel Occlusion (LVO) AIS
Supporting Evidence: Potential Effect on Large Vessel Occlusion (LVO) AIS AI imaging analysis｜LT3001-205 Phase 2 trial (Phase 2 trial in US, EU, TW, n=88, early termination in 2025)
Slide 12: AI Imaging Analysis: LT3001 Efficacy Signal in LVO-like Stroke
AI Imaging Analysis: LT3001 Efficacy Signal in Large Vessel Occlusion-Like (LVO-like) Stroke AI imaging analysis｜LT3001-205 (Phase 2 trial) • AI imaging biomarkers: Serial cross-timepoint tracking of infarct volume, perfusion status, and thrombus morphology • Efficacy signal: LT3001 demonstrates gre
Slide 13: LT3001-EVT: Enhancing EVT Efficacy Study – Developing a Second Indication
LT3001-EVT: Enhancing EVT Efficacy Study – Developing a Second Indication Status: Trial design in progress Why LT3001 is needed Study Goal: Study Design: after EVT: Evaluate multi-dose LT3001 efficacy in improving EVT treatment • Double-blind, placebo-controlled, multi- national, multi-center phase
Slide 14: LT3001: Clinical Development Program – Establishing a New Treatment Standard for Stroke
LT3001: Clinical Development Program – Establishing a New Treatment Standard for Stroke • INDs active across US, EU, China, UK, and Taiwan • Fast Track Designation (FTD) granted by the US FDA 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 US TW CN FTD, US EU Phase 3 NDA N
Slide 15: LT3001 Clinical Need x Commercial Value
LT3001 Clinical Need x Commercial Value Novel mechanism x established clinical PoC x de-risked development pathway - potential global blockbuster asset capable of transforming stroke treatment paradigms More than 7 million AIS patients globally; the majority lack access to Large Market × High effect
Slide 16: Lumosa Pipeline
NB rasa szss UMOSA Lumosa Pipeline (a.
Slide 17: Lumosa Business Model
Lumosa Business Model Focus on innovative neurological disease therapies, accelerate clinical proof- of-concept (PoC) validation, drive global asset licensing and maximize company value Lumosa collaboration partners: International pharma: Innovative programs, CMC development, early clinical validati
Slide 18: Lumosa: Focused Development of Innovative Therapies for Neurological Diseases (FIC, BIC)
Lumosa: Focused Development of Innovative Therapies for Neurological Diseases (FIC, BIC) Asset Indication Modality IND/ IIT Phase 1 Phase 2 Phase 3 NDA Market Post-operative Small molecule, LT-1001 Taiwan, Singapore, Thailand, Malaysia, Ukraine pain 505B2 Acute ischemic Peptide-small 2026 Q4 Phase 2
Slide 19: Thank You
Lumosa – A new drug development company with global licensing capabilities focusing on the development of innovative therapies for neurological diseases Thank You
Lumosa Therapeutics — Institutional Investor Conference 2026 on 6ix